|1.31||-0.0600||-4.38%||Vol 61.71K||1Y Perf -18.93%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||5.00||Analyst Rating||Strong Buy 1.00|
|Potential %||281.68||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||100/100/100||Value Ranking||★+ 43.61|
|Insiders Value % 3/6/12 mo.||100/100/100||Growth Ranking||★★★+ 53.96|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/100||Income Ranking||— -|
|Price Range Ratio 52W %||33.68||Earnings Rating||—|
|Market Cap||29.78M||Earnings Date||10th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||27.33K|
|Avg. Monthly Volume||84.30K|
|Avg. Quarterly Volume||53.97K|
Cyclo Therapeutics Inc. (NASDAQ: CYTH) stock closed at 1.31 per share at the end of the most recent trading day (a -4.38% change compared to the prior day closing price) with a volume of 61.71K shares and market capitalization of 29.78M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 8 people. Cyclo Therapeutics Inc. CEO is N. Scott Fine.
The one-year performance of Cyclo Therapeutics Inc. stock is -18.93%, while year-to-date (YTD) performance is -7.75%. CYTH stock has a five-year performance of %. Its 52-week range is between 0.67 and 2.57, which gives CYTH stock a 52-week price range ratio of 33.68%
Cyclo Therapeutics Inc. currently has a PE ratio of -1.20, a price-to-book (PB) ratio of 3.12, a price-to-sale (PS) ratio of 14.41, a price to cashflow ratio of 63.20, a PEG ratio of -, a ROA of -135.45%, a ROC of -198.39% and a ROE of -200.35%. The company’s profit margin is -%, its EBITDA margin is -754.80%, and its revenue ttm is $1.19 Million , which makes it $0.13 revenue per share.
Of the last four earnings reports from Cyclo Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Cyclo Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Cyclo Therapeutics Inc. is Strong Buy (1), with a target price of $5, which is +281.68% compared to the current price. The earnings rating for Cyclo Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cyclo Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cyclo Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 57.90, ATR14 : 0.16, CCI20 : -14.37, Chaikin Money Flow : -0.02, MACD : 0.05, Money Flow Index : 33.53, ROC : -6.43, RSI : 49.99, STOCH (14,3) : 42.75, STOCH RSI : 0.00, UO : 35.47, Williams %R : -57.25), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cyclo Therapeutics Inc. in the last 12-months were: F. Patrick Ostronic (Buy at a value of $7 485), Fine N. Scott (Buy at a value of $212 575), Francis Patrick Ostronic (Buy at a value of $7 785), Jeffrey Tate (Buy at a value of $42 516), Markus Sieger (Buy at a value of $7 485), N. Scott Fine (Buy at a value of $37 425)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.